Intech Investment Management LLC Sells 30,447 Shares of Omnicell, Inc. $OMCL

Intech Investment Management LLC cut its stake in Omnicell, Inc. (NASDAQ:OMCL) by 57.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 22,121 shares of the company’s stock after selling 30,447 shares during the period. Intech Investment Management LLC’s holdings in Omnicell were worth $1,002,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of Omnicell in the second quarter valued at about $26,000. Clearstead Advisors LLC raised its position in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares during the period. First Horizon Corp raised its position in shares of Omnicell by 54.6% in the fourth quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after purchasing an additional 564 shares during the period. LSV Asset Management bought a new position in shares of Omnicell in the third quarter valued at about $97,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after purchasing an additional 3,932 shares during the period. 97.70% of the stock is owned by institutional investors.

Omnicell Price Performance

NASDAQ:OMCL opened at $43.00 on Monday. Omnicell, Inc. has a 52 week low of $26.84 and a 52 week high of $55.00. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 97.73, a P/E/G ratio of 1.11 and a beta of 0.97. The firm’s 50-day simple moving average is $39.86 and its 200 day simple moving average is $41.37. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. During the same period last year, the firm earned $0.26 earnings per share. Omnicell’s revenue for the quarter was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, sell-side analysts predict that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Insider Activity

In other Omnicell news, EVP Corey J. Manley sold 7,405 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $34.69, for a total value of $256,879.45. Following the transaction, the executive vice president directly owned 96,717 shares of the company’s stock, valued at $3,355,112.73. This trade represents a 7.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 15,520 shares of company stock worth $607,610. Insiders own 2.92% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Benchmark reissued a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. KeyCorp raised their price target on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 28th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Zacks Research raised shares of Omnicell from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Finally, UBS Group set a $60.00 price target on shares of Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Omnicell currently has a consensus rating of “Buy” and an average price target of $59.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.